Table 3.
Case series and retrospective cohort studies on rituximab for recurrent membranous nephropathy
| Study | Design | Total n | Recurrence Treatment | Dose of Rituximab | Clinical Condition At Last Follow-up | Follow-up (Months) | Adverse Effects |
|---|---|---|---|---|---|---|---|
| El-Zoghby et al. 2009 (93) | Retrospective, single center | 8 | RTX | 2 doses of 1000 mg 2 weeks apart | PR/CR: 6 out of 8 (75%) Relapsea: 1 (13%) For 1 patient, no long-term data were available |
Mean 37 (SD ± 31) | 2 patients required hospitalization for infection 9 and 12 months after treatment |
| Sprangers et al. 2010 (94) | Case series | 4 | RTX + steroids | 4 weekly doses of 375 mg/m2 or 2 doses of 1000 mg 2 weeks apart | Proteinuria decreased from 4 g/24 h to 1.8 g/24 h | Mean 81 (SD ± 41) | No |
| Spinner et al. 2015 (95) | Part of retrospective cohort study | 3 | RTX | Single dose of either 200 mg or 500 mg | CR: 3 out of 3 patients (100%) | Median 25 (IQR 12–43) | N/A |
| Makhdoomi et al. 2015 (96) | Case report | 2 | RTX | 4 doses of either 600 mg or 900 mg every 2 weeks | CR: 2 out of 2 patients (100%) | 36, 18 | No |
| Kattah et al. 2015 (35) | Case series | 11 | RTX | Not stated | CR: 5 out of 11 (45%) PR: 2 out of 11 (18%) NR: 4 out of 11 (36%) |
Median 88 (IQR 64–122) | N/A |
| Quintana et al. 2015 (36) | Case series | 6 | RTX (n=3) RTX + PP (n=3) |
RTX: 4 weekly doses of 375 mg/m2 PP: 7 exchanges over the course of 14 days |
CR: 1 out of 6 (17%) PR: 3/6 (50%) NR: 1 out of 6 (17%) For 1 patient, no long-term data were available |
Median 141 | No |
| Gupta et al. 2016 (97) | Case series | 6 | RTX | 1–2 doses of 375 mg/m2 2 weeks apart |
PR: 5 out of 6 (83%) For 1 patient, no long-term data were available |
Median 70 (IQR 12–108) | No |
| Grupper et al. 2016 (34) | Retrospective cohort study | 17 | RTX + steroids | 2 doses of 1000 mg 2 weeks apart | CR: 9 out of 17 (53%) PR: 5 out of 17 (29%) NR: 3 out of 17 (18%) |
Median 87.5 (IQR 42.7–139) | 5 patients required hospitalization due to infection within 2 years after treatment |
RTX, rituximab; CR, complete remission (defined as proteinuria ≤0.3 g/24 h with a stable kidney function); PR, partial remission (defined as reduction of 50% in baseline proteinuria <3.5 g/24 h with a stable kidney function); SD, standard deviation; IQR, interquartile range; N/A, not available; NR, no remission; PP, plasma exchange.
a
Relapse was defined as proteinuria ≥3.5 g/24 h after a period of CR or PR.